BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy
Crossref DOI link: https://doi.org/10.1007/s13277-015-3061-7
Published Online: 2015-01-24
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bouchalova, Katerina
Svoboda, Marek
Kharaishvili, Gvantsa
Vrbkova, Jana
Bouchal, Jan
Trojanec, Radek
Koudelakova, Vladimira
Radova, Lenka
Cwiertka, Karel
Hajduch, Marian
Kolar, Zdenek
Text and Data Mining valid from 2015-01-24